← All trials
NCT04341311
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Apr 10, 2020
- Last posted
- Apr 10, 2020
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- CelgeneCollaborator
- SecuraCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.